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The androgen-regulated Calcium-Activated Nucleotidase 1
(CANT1) is commonly overexpressed in prostate cancer and is
tumor-biologically relevant in vitro
Abstract
Previously, we identified the calcium-activated nucleotidase 1 (CANT1) transcript as up-regulated in
prostate cancer. Now, we studied CANT1 protein expression in a large cohort of nearly 1000 prostatic
tissue samples including normal tissue, prostatic intraepithelial neoplasia (PIN), primary carcinomas,
metastases, and castrate-resistant carcinomas, and further investigated its functional relevance. CANT1
displayed predominantly a Golgi-type immunoreactivity with additional and variable cytoplasmic
staining. In comparison to normal tissues, the staining intensity was significantly increased in PIN
lesions and cancer. In cancer, high CANT1 levels were associated with a better prognosis, and
castrate-resistant carcinomas commonly showed lower CANT1 levels than primary carcinomas. The
functional role of CANT1 was investigated using RNA interference in two prostate cancer cell lines
with abundant endogenous CANT1 protein. On CANT1 knockdown, a significantly diminished cell
number and DNA synthesis rate, a cell cycle arrest in G(1) phase, and a strong decrease of cell
transmigration rate and wound healing capacity of CANT1 knockdown cells was found. However, on
forced CANT1 overexpression, cell proliferation and migration remained unchanged. In summary,
CANT1 is commonly overexpressed in the vast majority of primary prostate carcinomas and in the
precursor lesion PIN and may represent a novel prognostic biomarker. Moreover, this is the first study to
demonstrate a functional involvement of CANT1 in tumor biology.
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Abstract. 
Previously, we identified the Calcium-activated nucleotidase 1 (CANT1) transcript as 
upregulated in prostate cancer. Now, we studied CANT1 protein expression in a large 
cohort of nearly 1000 prostatic tissue samples including normal tissue, prostatic 
intraepithelial Neoplasia (PIN), primary carcinomas, metastases and castrate 
resistant carcinomas and further investigated its functional relevance. CANT1 
displayed predominantly a Golgi-type immunoreactivity with additional and variable 
cytoplasmic staining. In comparison to normal tissues, the staining intensity was 
significantly increased in PIN lesions and cancer. In cancer, high CANT1 levels were 
associated with a better prognosis and castrate resistant carcinomas commonly 
showed lower CANT levels than primary carcinomas. The functional role of CANT1 
was investigated using RNA interference in two prostate cancer cell lines with 
abundant endogenous CANT1 protein. Upon CANT1 knockdown a significantly 
diminished cell number and DNA synthesis rate, a cell cycle arrest in G1-phase and a 
strong decrease of cell transmigration rate and wound healing capacity of CANT1 
knockdown cells was found. However, upon forced CANT1 overexpression cell 
proliferation and migration remained unchanged. 
In summary, CANT1 is commonly overexpressed in the vast majority of primary 
prostate carcinomas and in the precursor lesion PIN and may represent a novel 
prognostic biomarker. Moreover, this is the first study to demonstrate a functional 
involvement of CANT1 in tumorbiology. 
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Introduction. 
Prostate cancer is the most common malignancy in men in western countries 
1-2 and its carcinogenesis is still incompletely understood. For the development of 
more efficient therapies, elucidating the molecular processes of prostate cancer 
progression is of primordial importance. Furthermore, biomarkers that facilitate the 
diagnosis of prostate cancer at an early stage and allow the differentiation between 
insignificant and potentially aggressive carcinomas are urgently needed. Previously, 
we have conducted an array based transcript analysis of matched normal tissue and 
prostate cancer to identify differentially expressed genes as candidates for further 
research. Among the top upregulated genes in prostate cancer was Calcium-
activated nucleotidase 1 (CANT1), which has hitherto not been characterized further 
in human neoplasias. In a multi tissue screen, Smith et al. 3 described expression of 
CANT1 mRNA in various organs being strongest in testis, placenta, small intestine 
and prostate. The CANT1 protein acts as apyrase and hydrolyzes di- and 
triphosphates in a calcium-dependent manner, preferably UDP, GDP and UTP 3-4. 
Since CANT1 is androgen regulated 5, its analysis in a primarily androgen dependent 
tumor is of particular interest and has not been conducted so far. 
The objective of this study was to clarify the diagnostic and prognostic properties and 
the functional role of CANT1 in prostate cancer. CANT1 protein expression was 
analyzed in two independent cohorts of clinically characterized human prostate 
cancer cases, together representing nearly 1000 patients. A recurrent overexpression 
of CANT1 protein in human prostate cancer tissues and already in Prostatic 
Intraepithelial Neoplasia (PIN) lesions is demonstrated, indicating that CANT1 
upregulation might be an early event during prostate carcinoma development. A 
subtle analysis of CANT1 overexpression further demonstrated that very high 
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expression rates in carcinomas correlates with better patient prognosis. Cell culture 
studies did not reveal an increase of proliferative or migratory capacity upon CANT1 
overexpression. However, we show that CANT1 knockdown leads to a reduced cell 
proliferation and migration rate of prostate cancer cell lines and thus constitute for the 
first time a functional relevance of CANT1 in prostate carcinomas. 
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Material & Methods. 
Patients and tissue microarray description. 
Two tissue microarrays (TMA) were used to follow CANT1 expression during 
prostate cancer progression and to evaluate the diagnostic and prognostic potential 
of CANT1 immunohistochemistry.  
TMA #1 consists of formalin-fixed paraffin-embedded prostate tissues from 
529 patients, who were diagnosed at the Institute of Surgical Pathology, University 
Hospital Zurich, between 1993 and 2006 6. Clinical follow up data were available for 
201 patients following radical prostatectomy (RPE). Seventy-nine patients (39%) 
experienced a PSA-relapse, defined as a rising PSA level exceeding 0.1 ng/ml, 
having reached a nadir after surgery. The median follow up time (of all patients) was 
67 months. The TMA was constructed as described 6, briefly, each case was 
represented by a single 0.6mm core of tissue. 349 of 529 cores were evaluable for 
CANT1 staining. These cases represent 30 benign hyperplasias of the prostate, 269 
primary prostate carcinomas (for demographics see Table 1) and 50 advanced cases 
that are either derived from lymph node or organ metastases (29) or from castrate 
resitant carcinomas (21). This study was approved by the Cantonal Ethics Committee 
of Zurich (StV 25-2007). 
Formalin-fixed paraffin-embedded prostatectomy specimens from 640 patients who 
underwent radical prostatectomy between 1999 and 2005 at the Department of 
Urology, Charité Universitätsmedizin Berlin, were included in TMA #2 (for 
demographics see Table 2), which was constructed as described 7-9 and approved by 
the Charité University Ethics Committee (EA1/06/2004) on 20 September 2004. 
Eighty-five patients (14.6%) experienced a PSA relapse. The median follow-up time 
of all cases was 47.5 months. Each case is represented by 5 cores of 2 mm in 
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diameter each, encompassing benign prostatic hyperplasia (BPH) of the transitional 
zone, normal tissue from the peripheral zone, prostatic intraepithelial neoplasia (PIN), 
if present (otherwise another core from the peripheral zone), and two cores of 
invasive carcinoma, ideally of primary and secondary Gleason score. CANT1 staining 
of normal and cancerous cores was evaluable for 618 patients, the PIN core was 
evaluable for 467 patients. 
 
Immunohistochemistry and immunofluorescence.  
Freshly cut sections (3 µm) from the TMA blocks were analyzed by 
immunohistochemistry using the Ventana Benchmark automated staining system 
(Ventana Medical Systems, Tucson, AZ) and Ventana reagents according to the 
manufacturer’s recommendations. Following antigen retrieval using the “CC1 
protocol”, the CANT1 antibody (Abnova, clone 2D3, Taipei, Taiwan; 1:300) was 
detected by the UltraVIEW DAB detection kit. Subsequently, the slides were 
counterstained with haematoxylin, dehydrated and mounted.  
 
Evaluation of CANT1 immunohistochemistry. 
On TMA #1, CANT1 staining intensity was evaluated by two clinical 
pathologists (GK, FRF) using a scoring system that differentiates between negative 
(0), weak (1), moderate (2) and strong (3) staining. Since TMA #2 with its multiple 
cores and the larger diameter per core allowed a better estimation of intratumoral 
heterogeneity, a more differentiated evaluation scheme was applied in addition to the 
simpler 0-3+ rating. A Histochemical score (H-score) was set up to include the 
percentages of weak, moderate and strong expression and to sum these up in a 
 - 7 - 
weighted manner (H-score = (1 * percentage weak) + (2 * percentage moderate) + (3 
* percentage strong)), this evaluation was carried out by the pathologists CS and GK. 
To proof antibody specificity, two consecutive slides were stained as described 
above (antibody dilution 1:1000). The antibody solution for one slide was pre-
incubated with CANT1 recombinant protein (Abnova, Q1) 100 times in access 
overnight at 4 °C. 
Immunofluorescence double stainings were performed as described previously 
7 using the same CANT1-antibody as for immunohistochemistry (1:300) and a 
GOLPH2 polyclonal rabbit-antibody (Abcam, ab22209, Cambridge, MA, 1:100). 
 
Ultracentrifugation and precipitation of supernatants. 
 After pelleting cell debris supernatants were transferred to Ultra-Clear 
cenctrifuge tubes (Beckmann, Palo Alto, CA) and vesicles were separated by 
ultracentrifugation in a SW32.1 Ti rotor for 2.5 h at 24’000 rpm and 4°C. 
Supernatants were then precipitated by adding trichloroacetic acid to a final 
concentration of 10% and washing the pellets with icecold acetone.  
 
Serological Tests. 
Serum samples (n=38) were collected from 23 consented prostate cancer 
patients and 15 healthy individuals and submitted to an Enzyme-Linked 
Immunosorbent Assay (ELISA) for detection of serum CANT1 (sCANT1). The ELISA 
was performed as a sandwich ELISA as follows: Maxisorb plates (NUNC, 
Langenselbold, Germany) were coated overnight at 4°C with 1 μg/ml purified 
monoclonal mouse immunoglobulin against CANT1 (Abnova, clone 2D3, Taipei, 
Taiwan). The following day, plates were washed with PBS and blocked using 10% 
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BSA and 0.5% Tween 20 (Sigma-Aldrich, St. Louis, MO) for 1 hour at room 
temperature. Samples were diluted 1:10 and applied in triplicate to the plate for 1.5 
hours at room temperature. Recombinant CANT1 protein (Abnova, P01) was plated 
in increasing concentrations (0.05 µg/ml, 0.1 µg/ml, 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 
µg/ml, 10 µg/ml and 20 µg/ml). Then plates were incubated with polyclonal rabbit 
serum against CANT1 (Sigma-Aldrich, 1:500) for 1 hour at room temperature that 
was detected by the horseradish linked secondary anti-rabbit antibody (Sigma-
Aldrich, 1:4’000, for 45 min). Inbetween each incubation step, plates were extensively 
washed. Wells were replenished with 100 μl staining solution (TMBsolution, Pierce 
Biotechnology, Rockford, IL) per well and left at room temperature in the dark for 20 
minutes. The colour reaction was stopped by adding 50 μl 2 N H2SO4 to each well. 
The absorbance at 450 nm was measured using an Emax microplate reader 
(Molecular devices, Sunnyvale,CA) and analyzed with Softmax Pro V3.0 software.  
 
Cell culture. 
PC-3, DU-145 (both ATCC, Manassas, VA) and LNCaP cells (DSMZ, 
Braunschweig, Germany) were cultivated in Ham’s F-12 Medium/Kaighn’s 
Modification, Eagle’s Minimal Essential Medium and RPMI-1640 Medium, 
respectively, each supplemented with 10% FBS. RWPE-1 cells (ATCC) were grown 
in Keratinocyte Serum Free Medium mixed with bovine pituitary extract and human 
recombinant epidermal growth factor (all cell culture media and supplements 
invitrogen, Carlsbad, CA). All cell lines were cultured at 37 °C, 5% CO2 and 100% 
humidity. 
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 RNA isolation and quantitative real-time reverse transcription PCR (QRT-PCR). 
RNA was isolated using the RNeasy kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions, followed by cDNA synthesis applying the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). 
Quantitative real-time PCR (primer CANT1: 5’CTGGGTGTCCAACTACAACG3’, 
5’ACTCCAGCAGGCAGACTCAT3’; probe #42) was performed on the 7900HT Fast 
Real-Time PCR System using TaqMan Mastermix (both Applied Biosystems) and the 
Universal Probe Library (Roche Applied Science, Mannheim, Germany) according to 
the recommendations of the manufacturer. Gene expression was normalized to 
ALAS1 (primer: 5’TAATGACTACCTAGGAATGAGTCG3’, 
5’CCATGTTGTTTCAAAGTGTCCA3’, all primers Microsynth, Balgach, Switzerland; 
probe #43), which is stably expressed in prostate cancer cells 10. 
 
Cell lysis and Western Blot analysis. 
Cells were lysed in 60 mM n-Octyl-ß-D-glucopyranoside (Sigma-Aldrich, St. 
Louis, MO) in the presence of protease inhibitors (complete, Mini, EDTA-free, 
Protease Inhibitor cocktail tablets; Roche Applied Science, Mannheim, Germany). 
Twenty μg of cleared lysates were separated by SDS-PAGE and transferred onto a 
polyvinylidene fluoride-membrane (Bio-Rad, Hercules, CA). After blocking with 1% 
BSA in PBS-Tween, membranes were probed with primary antibodies (CANT1 
Abnova, clone 2D3, Taipei, Taiwan; Actin, MAB1501 Millipore, Billerica, MA; tGFP, 
OriGene, Rockville, MD) followed by horseradish peroxidase-conjugated anti-mouse 
secondary antibody (Pierce Biotechnology, Rockford, IL) incubation and detection via 
SuperSignal West Dura Extended Duration Substrate (Pierce Biotechnology). 
 - 10 - 
 Transient gene knockdown and overexpression. 
For transient gene knockdown, LNCaP cells were transfected immediately 
after seeding using HiPerFect transfection reagent (Qiagen, Hilden, Germany) 
following the FastForward Protocol provided by the manufacturer. PC-3 cells were 
transfected using Lipofectamine 2000 (invitrogen, Carlsbad, CA) as transfection 
reagent. Cells were transfected at the day of seeding with a final siRNA concentration 
of 10 nM (target sequences: unspecific AATTCTCCGAACGTGTCACGT, CANT1 
siRNA #1 CCAGATCATTGTGGCCCTCAA, CANT1 siRNA #2 
ACCCGGAATGGAATGAGTCTA, Qiagen). One day after transfection the medium of 
PC-3 cells was changed. Knockdown efficiency was confirmed on RNA and protein 
level using QRT-PCR and Western Blot analysis, respectively. 
For transient overexpression, RWPE-1 cells were transfected at 80% density 
with FuGENE 6 transfection reagent (Roche Applied Science, Mannheim, Germany) 
according to the manufacturer’s protocol. For 6 cm-dishes 20 µl transfection reagent 
and 8 µg of pCMV6-AN-GFP (named GFP) or pCMV6-XL6-CANT1 (named CANT1, 
both OriGene, Rockville, MD) were used. 
 
DNA synthesis rate. 
The DNA synthesis rate was measured based on bromodeoxyuridine (BrdU) 
incorporation into newly synthesized DNA strands applying the Cell Proliferation 
ELISA, BrdU kit (Roche Applied Science, Mannheim, Germany) according to the 
manufacturer’s instructions. Briefly, cells were seeded in 96 well-plates, after 6 hours, 
BrdU labeling reagent was added to the medium and cells were incubated at 37 °C 
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over night. Subsequently, cells were fixed and stained with an anti-BrdU antibody, 
which was detected with substrate solution. The color reaction was stopped by 
adding sulphuric acid and the optical density was measured at 450 nm and at 595 
nm as reference wavelength using the infinite F200 microplate reader (Tecan, 
Männedorf, Switzerland). 
 
Cell cycle analysis. 
 Cells were detached, washed twice with sample buffer (1% Glucose in PBS) 
and fixed with 70% ethanol overnight at 4 °C. The next day, cells were incubated with 
50 µg/ml propidium iodide (Sigma-Aldrich, St. Louis, MO), 0.3 mg/ml RNaseA 
(Qiagen, Hilden, Germany) and 0.05% Triton X-100 (Sigma-Aldrich) in sample buffer 
and analyzed by flow cytometry. Proportion of cells in G1-, S- and G2/M-phase was 
determined applying the Dean/Jett/Fox-model provided by the FlowJo 6.3 software. 
 
Transmigration assay. 
Haptotactic cell migration was analyzed in a modified boyden chamber assay. 
Transwell chambers (Corning, Corning, NY) that were coated at the bottom side with 
10 µg/ml fibronectin (Roche Applied Science, Mannheim, Germany) for 2 hours at 
room temperature. The lower chamber was filled with serum free RPMI-1640 Medium 
supplemented with 0.5% BSA (Sigma-Aldrich, St. Louis, MO) for transmigration of 
LNCaP and PC-3 cells, Keratinocyte Serum Free Medium without supplements with 
0.5% BSA was used in case of RWPE-1 cells . Cells were seeded in the upper 
chamber in the corresponding medium. After 24 hours incubation at 37 °C non-
migrated cells were removed with a cotton swab and the remaining cells were fixed 
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with methanol/acidic acid and stained with DAPI (Sigma-Aldrich). Pictures were taken 
at 9 defined places of the membrane and analyzed with ImageJ 1.4 software. The 
migration rate was quantified by determining the area of the membrane that was 
covered with stained nuclei. 
 
Scratch wound assay. 
Cells were seeded in 6 cm-cell culture dishes and grown to 95% density, 
before they were transfected with siRNAs. A wound was introduced into the cell 
monolayer using a pipette tip and pictures were taken every 24 hours. The area of 
the wound was measured using ImageJ 1.4 software. 
 
Statistical analysis. 
Mean CANT1 staining intensities were compared between different groups of 
tumor stage using the Mann-Whitney Test in cohort #1 and the Wilcoxon Matched-
pairs Test in cohort #2. For analysis of the association of staining intensity with 
clinicopathological parameters cross tables were calculated (chi square test, 2-tailed 
Fisher’s exact test). Univariate survival analyses were conducted according to 
Kaplan-Meier (log rank test). These statistics were calculated with PASW18 (SPSS, 
Chicago, IL). Mean serum ELISA levels were compared with help of the 2-tailed 
unpaired t-test. 
The cell culture results are displayed as mean ± standard deviation, each 
experiment was repeated at least three times if not otherwise indicated, significance 
was tested in a 2-tailed paired or unpaired t-test if necessary with Welch’s correction, 
depending on the data set. 
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Results. 
CANT1 protein is overexpressed in human prostate cancers. 
Previously, we have reported an overexpression of CANT1 mRNA in human 
prostate carcinoma tissue compared to adjacent normal tissue 11. In order to confirm 
the results on protein level and to evaluate the diagnostic and prognostic potential of 
CANT1 expression, two TMAs representing 989 patients were stained for CANT1. 
Before, the specificity of the CANT1 monoclonal antibody was verified applying two 
approaches. First, CANT1 was knocked down in LNCaP and PC-3 cells, which 
express high levels of CANT1 endogenously, and detection by Western blot analysis 
with the candidate antibody was monitored. Corresponding to the strong reduction of 
CANT1 mRNA, the Western blot band disappeared upon transfection with both 
CANT1 specific siRNAs (see paragraph “Characterization of CANT1 expression in 
prostatic cell lines.”) showing that there is no cross-reactivity with other molecules. In 
the second approach, substantiating the specificity of the used CANT1 antibody, the 
immunohistochemical staining was completely blocked after pre-incubation of the 
antibody with CANT1 recombinant protein (see Supplemental Figure S1 at 
http://ajp.amjpathol.org).  
In general, CANT1 immunoreactivity was detected in the cytoplasm apically 
close to the nucleus, resembling a Golgi apparatus staining pattern (Fig. 1a). 
Additionally, a diffuse cytoplasmic staining was observed in some cases (Fig.1 c,d), 
which was recorded separately on TMA #1. In normal tissue, CANT1 staining was 
only detected in secretory epithelia, whereas basal cells were generally negative for 
CANT1 (Fig. 1a).  
On TMA #1, which contains samples from 30 normal cases, 269 primary 
carcinomas, 29 metastases and 21 castrate resistant prostate carcinomas, CANT1 
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staining intensity was monitored throughout carcinoma progression. The mean 
intensity of Golgi and cytoplasmic staining was 1.4 and 0.4 in normal tissue, 2.3 and 
1.2 in primary carcinomas, 2.3 and 1.3 in metastases (lymph node metastasis in Fig. 
1d) and 1.9 and 0.7 in castrate resistant carcinomas, respectively (Fig. 2a). The 
difference in the mean staining intensity of CANT1 between normal tissues and 
primary carcinomas, metastases as well as all cancerous tissues was highly 
significant for Golgi staining as well as for cytoplasmic staining. However, only the 
Golgi staining intensity was significantly different between normal tissues and 
castrate resistant carcinomas (Table 3). 
On TMA #2 the mean intensity of CANT1 Golgi staining was 1.0 in the normal 
cores, 1.7 in the PIN cores and 1.8 in the carcinoma cores (Fig. 2c). In addition, the 
composition of TMA #2 allowed to directly compare CANT1 staining intensity 
between cancerous and adjacent normal tissue from each patient. To detect also 
subtle differences between carcinoma and normal cores that would in some cases be 
assigned the same staining score, it was also reported if the cancer was area stained 
stronger than adjacent normal glands. This was found in 97.2% of the cases 
(example in Fig. 1b). 
Altogether, these data confirm the overexpression of CANT1 in human 
prostate carcinomas compared to normal prostate epithelium, which was reported on 
mRNA level before, also on protein level. Additionally it was shown, that this 
upregulation occurs already in PIN lesions. Further, a slight reduction of CANT1 
expression was noted in castrate resistant carcinomas. 
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 CANT1 expression, clinicopathological associations and survival analysis. 
For statistical analyses of cohort #1 (crosstables and survival analyses) both 
staining qualities were dichotomized by the median into low and high groups (Golgi 
pattern: 0, 1, 2 vs. 3; cytoplasmic pattern: 0, 1 vs. 2, 3). No correlations of Golgi and 
cytoplasmic CANT1 staining with patient age, Gleason score, pT stage and margin 
status were found. However, cytoplasmic CANT1 staining correlated negatively with 
serum PSA-levels (p=0.026) (Table 1). In cohort #2 CANT1 staining intensity 
(dichotomized by H-score 1.9) did not correlate with patient age, serum PSA-levels 
and margin status. A trend between high Gleason grade and low H-score was noted 
and as well as a significant correlation between high pT stage and low H-score 
(Table 2). 
On univariate analysis of PSA relapse free survival times no association of 
CANT1 tissue levels with disease relapse was found on TMA #1, neither for the Golgi 
nor the cytoplasmic staining (Fig. 2b). However, due to the larger cores of TMA #2 it 
was possible to also consider heterogeneity of CANT1 staining and to derive a more 
differentiated H-score. A careful analysis of these data revealed a good prognosis of 
patients with the highest CANT1 expression (the upper quartile), whereas the 
majority of the patients experienced a PSA relapse much earlier (Fig. 2d). However, 
this survival difference was not detectable, when only the simpler overall intensity 
score (0-3) was analyzed (data not shown). 
 
Cellular localization of CANT1. 
In transfected CHO cells the full length rat homologue of CANT1 localizes to 
the membranes of the endoplasmic reticulum (ER) and pre-Golgi intermediates 12 
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whereas a truncated form of the human nucleotidase was detected in the 
supernatant of transfected COS-1 cells, indicating cleavage and secretion 3. To 
analyze the localization of CANT1 in human tissues, double immunofluorescence 
stainings of normal and cancerous prostate tissue with GOLPH2, a known Golgi 
protein 13, were performed. An extensive overlap of both staining patterns was seen, 
illustrating that CANT1 is predominantly localized in the Golgi apparatus. An 
additional diffuse CANT1 staining was observed in the cytoplasm in some cases (Fig. 
3).  
We next examined if CANT1 is also secreted by cells that express the protein 
endogenously. Thus, serum-free supernatants from LNCaP and PC-3 cells were 
collected and precipitated. The Western blot analysis showed that a shortened form 
of CANT1, which was approximately 2 kDa smaller compared to the band from the 
cell lysate (compare lane 2 and 3 to lane 1), was detectable in the supernatants of 
both cell lines before as well as after ultracentrifugation (Fig. 4a). 
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CANT1 is detectable in an ELISA assay. 
The confirmation of the secretion of CANT1 prompted us to establish a 
sandwich ELISA assay to clarify if CANT1 is detectable in human serum. When 
testing commercially available antibodies we found the combination of mouse 
monoclonal CANT1 antibody (Abnova) for capturing the antigen and rabbit polyclonal 
CANT1 antibody (Sigma-Aldrich) for detection to be the most reproducible design. 
Using this ELISA CANT1 serum levels appeared to be too low for quantification in 
this system with a detection range from 0.1 to 20 µg/ml. Therefore results are shown 
as measurement of absorbance at 450 nm. 
CANT1 serum levels in 23 tested patients with prostate cancer were slightly higher 
than in 15 healthy controls, however, this difference failed statistically significance 
(median patients: 0.096, median controls: 0.061; Fig. 4b). No correlation was noted 
between serum PSA and serum CANT1 levels (data not shown). 
 
Characterization of CANT1 expression in prostatic cell lines. 
We next sought to test if CANT1 overexpression has a functional relevance in 
prostate cancer. Therefore, cell lines were evaluated for endogenous CANT1 
expression levels and selected for subsequent functional studies. The expression on 
gene and protein level was determined in an immortalized prostatic epithelial cell-line, 
RWPE-1, and in three metastasis-derived prostate cancer cell lines, LNCaP, DU-145 
and PC-3. As observed by Western blot analysis, CANT1 protein was strongly 
expressed in LNCaP and PC-3 cells whereas it was hardly detectable in DU-145 
cells. A clear but weak band was detected in the lysate of the epithelium derived cell 
line RWPE-1. Similarly, mRNA expression was strongest in LNCaP and PC-3 cells. 
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High levels of CANT1 mRNA were also detected in DU-145 and RWPE-1 cells (Fig. 
5a). According to the strong CANT1 expression on mRNA and protein level, LNCaP 
and PC-3 cells were chosen for knockdown studies. RWPE-1 cells were chosen for 
overexpression studies because of the low CANT1 protein level and the non-
cancerous background. 
A knockdown protocol based on RNA interference was established for both 
cell lines. QRT-PCR and Western blot analysis revealed a potent CANT1 knockdown 
on mRNA and protein level, respectively, 72 hours after siRNA transfection (Fig. 5b, 
c), the knockdown efficiency being higher with CANT1 siRNA #1 than #2. 
 
CANT1 knockdown reduces cell proliferation. 
One of the main characteristics of cancer cells is uncontrolled proliferation 14. 
To determine if CANT1 expression has an influence on prostate cancer cell 
proliferation, LNCaP and PC-3 cells were transfected with CANT1 specific siRNAs 
and cells were counted. Compared to unspecific siRNA transfected cells, the cell 
number of CANT1 siRNA #1 and #2 transfected LNCaP cells was reduced 
significantly by 17% and 21%. Although siRNA treatment itself strongly affected the 
propagation of PC-3 cells, the number of CANT1 siRNA #1 and #2 transfected cells 
was further decreased by 38% and 26% compared to control cells (Fig. 6a,b). To test 
whether the reduction of cell number upon CANT1 knockdown was caused by a 
reduction of cell proliferation rate, DNA synthesis rate was determined by measuring 
BrdU incorporation. As shown in Fig. 6c, 32% and 36% less BrdU was detected after 
transfection of LNCaP cells with CANT1 siRNA #1 and #2, respectively. The DNA 
synthesis rate of PC-3 cells was decreased highly significantly by 67% and 30% in 
CANT1 siRNA #1 and #2 transfected cells compared to unspecific siRNA transfected 
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cells (Fig. 6d). Taken together, these results show a potent reduction of proliferation 
of LNCaP and PC-3 cells after CANT1 knockdown. 
 
Recuded cell proliferation is associated with a G1-arrest. 
The observed reduction of cell proliferation upon CANT1 knockdown involved 
the question, if this was reflected in a change of cell cycle distribution. Hence, the 
proportion of cells in G1-, S- and G2/M-phase was determined by flow cytometry of 
propidium iodide stained cells. The proportion of LNCaP cells in G1-phase raised 
from 68% in control cells to 76% in CANT1 knockdown cells, whereas the proportion 
of cells in S-phase declined from 20% to 13% in the respective groups, the proportion 
of cells in G2/M-phase remained unchanged (Fig. 7a,c,e, see Supplemental Figure 
S2a at http://ajp.amjpathol.org). The differences were even more dramatic in PC-3 
cells. Sixty-three per cent of the cells treated with unspecific siRNA were in G1-phase 
in contrast to 81% and 76% of the cells treated with CANT1 specific siRNA #1 and 
#2, respectively. Different from the LNCaP cells, the proportion of cells in S- as well 
as G2/M-phase was altered in PC-3 knockdown cells. S-phase cells decreased from 
19% in the control cells to 6% and 12% in the knockdown cells, in parallel G2/M-
phase cells decreased from 17% to 11% in the corresponding groups (Fig. 7b,d,f, see 
Supplemental Figure S2b at http://ajp.amjpathol.org). 
Summarized, these data clearly indicate a G1-arrest upon CANT1 knockdown 
in LNCaP as well as PC-3 cells. 
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 Cell migration is inhibited upon CANT1 knockdown. 
An elevated migration rate is another important feature of malignant cells 14. 
The relevance of CANT1 expression during cell migration was elucidated in a 
transmigration assay. In particular, migration towards fibronectin was investigated. 
Downregulation of CANT1 reduced highly significantly migration of LNCaP cells 
through the porous membrane by 55% and 20% using siRNA #1 and #2 compared to 
control cells. The reduction of PC-3 cell migration accounts for 61% and 13% with the 
respective siRNAs (Fig. 8a,b). Migration of PC-3 cells on a plain surface was 
assessed in a scratch wound assay. The area, which was not recovered with 
migrated cells within 24 hours after introducing the wound, was 1.4 and 1.6 times 
larger following CANT1 downregulation with specific siRNA #1 and #2, respectively, 
compared to unspecific siRNA treatment (Fig. 8c), indicating a diminished cell 
motility. Altogether, these data show that the reduction of CANT1 expression induces 
strong inhibition of LNCaP and PC-3 cell migration. 
 
CANT1 overexpression neither influences cell proliferation nor cell migration. 
To check if enforced expression of CANT1 contrarily to CANT1 knockdown 
increases the proliferative and migratory capacity of prostatic cells, CANT1 was 
transiently transfected into the prostate epithelium derived, benign cell line RWPE-1 
and DNA synthesis rate and transmigration was measured. An increasing expression 
level of CANT1 was reached by transfecting the cells with a GFP vector as negative 
control, with a mixture of GFP and CANT1 vector, which consisted of 33% CANT1 
vector and 67% GFP vector to keep the DNA content constant, and with pure CANT1 
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vector. However, neither the DNA synthesis rate nor the transmigration rate of 
RWPE-1 cells changed upon CANT1 overexpression (Fig. 9). Similar results were 
obtained with the prostate cancer cell line DU-145, which expresses very low levels 
of CANT1 as well as with PC-3 cells, where a further increase of CANT1 expression 
was achieved by transient transfection (data not shown). These results show that 
increased expression of CANT1 does not increase the tumorigenic potential of 
prostatic cell lines.  
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Discussion. 
Although most tumors of the prostate are usually slowly growing and the 
majority of patients can be cured by either surgery or radiotherapy 15, a significant 
fraction of patients experiences disease progression. For these, treatment options 
are limited and the survival rates for late advanced, castrate resistant prostate 
carcinomas are low 16-19. To address these challenges, intensive research on reliable 
disease markers and elucidation of disease development on the molecular level is 
necessary. Previously, we identified CANT1 as a highly upregulated gene in human 
prostate cancer compared to adjacent normal tissue 11. Further, CANT1 gene 
expression has been shown to be significantly higher in tumors of the prostate 
compared to 28 other tumor entities 20. However, the clinical significance of CANT1 
expression in prostate cancer tissues and the functional significance of CANT1 
expression in cancer cells have not been investigated yet. Here, we report the first 
comprehensive analysis of CANT1 protein expression in prostatic tissues and cell 
lines. Main findings include a consistent overexpression of CANT1 protein in human 
prostate cancer that is already detectable in PIN lesions, a good prognosis for 
patients with very high rates of CANT1 in prostate cancer following prostatectomy 
and a reduction of cell proliferation and migration upon CANT1 downregulation in 
vitro, clearly showing a tumorbiological relevance of CANT1. 
After development of a valid immunohistochemistry protocol to allow specific 
detection of CANT1, nearly 1000 prostate tissue samples were analyzed in a TMA 
format as described 6-9. CANT1 immunoreactivity was detected in the Golgi 
apparatus region as well as in the cytoplasm. Evaluation of TMA #1 showed 
ubiquitous CANT1 expression in normal prostate epithelial tissue, however, the 
staining intensities of the Golgi apparatus and the cytoplasm were generally stronger 
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in carcinomas, thus suggesting CANT1 as a candidate diagnostic marker for prostate 
carcinomas. Slightly lower levels of CANT1 were noted in castrate resistant prostate 
carcinomas. The unique design of TMA #2 with matching normal and cancer tissues 
allowed to individually evaluate the diagnostic value of CANT1. Here, the 
upregulation of CANT1 in carcinomas could be convincingly confirmed. Moreover, the 
direct case wise comparison of cancerous and adjacent normal glands revealed a 
gain of CANT1 expression in 97.2% of the cases, clearly substantiating the 
applicability of CANT1 as potentially helpful ancillary marker to ascertain a cancer 
diagnosis in a suspicious lesion. Nevertheless, the diagnostic applicability of CANT1 
as a prostate cancer marker is hampered by its basal expression in normal glands 
and its inability to discriminate PIN glands from invasive carcinoma glands. 
The prognostic value of CANT1 appears to be limited, since the initial survival 
analysis of CANT1 expression categorized into negative, weak, moderate or strong 
expression did not show significant differences in Kaplan-Meier analyses. However, a 
significant impact towards better prognosis in cases with strong CANT1 
overexpression was noted in the larger study cohort (TMA #2) using a sophisticated 
semiquatitative evaluation scheme, which included area and intensity to compensate 
for expression heterogeneity. This more differentiated analysis allowed the 
separation of the upper quartile in the range of expression values, which was not 
feasible with the simpler three tier scoring system applied to cohort #1. This finding 
was further substantiated by the tendential and significant correlation between lower 
H-scores and higher Gleason scores and pT stages, respectively. These results 
nicely fit to the observation that CANT1 expression is lower in the aggressive group 
of castrate resistant carcinomas compared to primary carcinomas and suggests that 
rogression to castrate resistance is either accompanied or caused by a loss of 
CANT1. 
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In accordance with the overexpression of CANT1 in prostate carcinomas we 
detected higher CANT1-levels in patient sera compared to age matched healthy 
controls using a newly constructed sandwich ELISA assay, although, statistical 
significance was failed. Unfortunately, serum levels of CANT1 were in the range of 
the lower detection threshold of our assay (detection range from 0.1 to 20 µg/ml), 
which precluded exact quantification. Thus, we conclude that ELISA is not the ideal 
technique for serum measurements of CANT1 and that this protein may not be an 
ideal biomarker for routine laboratory tests. 
Concluding, we demonstrated a ubiquitous gain of CANT1 expression in 
prostate carcinomas compared to normal prostate epithelium in two independent 
cohorts. Yet, on account of the virtually equally intensive upregulation in PIN, CANT1 
is not recommended as a diagnostic tool for the surgical pathologist. However, a 
detailed analysis of CANT1 staining under consideration of its heterogeneity may 
help to differentiate between insignificant and potentially aggressive carcinomas at 
the time of prostatectomy.  
The recapitulation of the course of CANT1 expression during prostate cancer 
progression, being low in normal prostate epithelium and strong already in PIN lesion 
and remaining more or less constant in primary and advanced carcinomas, suggests 
that CANT1 upregulation is an early event. Therefore, it was encouraging to 
investigate if CANT1 has a tumor promoting function. For this, we set up an in vitro 
system to test cell proliferation and migration behaviour in CANT1 high and low cells. 
To analyze, if CANT1 has any transforming capacities, the prostate epithelial cell line 
RWPE-1, which expresses low CANT1 protein levels, was transfected with a CANT1 
vector. The analysis of cell proliferation rate via DNA synthesis rate measurement as 
well as the analysis of cell migration rate in a modified boyden chamber assay 
revealed no changes upon CANT1 overexpression. We next tested, if upregulation of 
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CANT1 leads to enhanced in vitro tumorigenicity of prostate cancer cells. This was 
not the case for DU-145 cells that are characterized by very low CANT1 protein 
levels. Similarly, proliferation and migration rates of PC-3 cells that endogenously 
express abundant CANT1 protein remained constant upon further enhancement of 
CANT1 expression (data not shown). We further investigated, if downregulation of 
CANT1 influences the tumorigenic potential of prostate cancer cells. Interestingly, 
CANT1 knockdown heavily impaired the function of both PC-3 cells and LNCaP cells, 
the latter being also characterized by high endogenous CANT1 protein levels. We 
showed that suppression of CANT1 expression slowed down propagation of LNCaP 
and PC-3 cells, which was caused by a reduced cell proliferation rate as 
demonstrated by DNA synthesis rate measurement. Cell cycle distribution analysis 
revealed that this reduction in turn was caused by an arrest in G1-phase. Consistent 
with the measurement of DNA synthesis rate, a similar reduction of the S-phase cell 
population was observed in the cell cycle study (compare Fig. 7c,d and Supplemental 
Figure S2 at http://ajp.amjpathol.org). Additionally, a decreased motility of both cell 
lines upon CANT1 downregulation was observed in the transmigration assay, which 
could be verified for PC-3 cells in the scratch wound assay. The latter assay is less 
reliably applicable to LNCaP cells as these do not build a dense monolayer. In most 
of the assays, the effect of CANT1 siRNA#1 was stronger than the effect of siRNA#2, 
which is consistent with the stronger reduction of CANT1 expression upon 
transfection with siRNA#1. This dose-dependency underlines the specificity of the 
effects, being indeed related to changes in CANT1 expression. These cell culture 
studies indicate that CANT1 overexpression alone is not sufficient to induce or 
enhance in vitro tumorigenicity of prostate epithelial or prostate cancer cells, 
respectively. However, CANT1 expression is essential to sustain cancer cell 
 - 26 - 
proliferation and migration. Thus, CANT1 appears to be relevant for the maintenance 
of prostate carcinomas. 
The questions arise, what leads to CANT1 upregulation during carcinogenesis 
and what is the reason for CANT1 decline in castrate resistant carcinomas? Which 
mechanisms underly the diminished tumorigenic potential of prostate cancer cell lines 
upon CANT1 knockdown? Why does the overexpression of CANT1 not induce an 
increase of in vitro tumorigenicity of prostatic cell lines? To answer these questions, 
knowledge about CANT1’s cellular function would be helpful. However, so far, very 
little is known about the biology of CANT1. In a study about MAPK and NFκB 
signaling CANT1 was identified as a novel candidate gene involved in these 
important cancer-related pathways. This genome wide study based on a luciferase 
reporter assay using constructs with promotors of MAPK target genes or promoters 
that contain NFκB binding sites revealed that CANT1 activates both pathways 21, 
which are frequently deregulated in tumorigenesis, including prostate cancer 22-26. 
The main function of CANT1 discussed currently is not related to 
carcinogenesis in particular, but regards the essential general cellular process of 
protein glycosylation. In its function as nucleoside-diphosphate (NDP)-hydrolase, 
CANT1 is suggested to be required for a continuous import of NDP-sugars into the 
ER or Golgi apparatus. The proposed mechanism is that CANT1 hydrolyzes NDP, 
which is a cleavage by-product after transfer of the sugar to the glycosylated protein. 
The resulting nucleoside-monophosphate (NMP) is then exported into the cytosol in 
exchange for a further NDP-sugar molecule 12, 27. Depending on its intracellular 
localization, CANT1 might thus influence three important cellular processes that are 
related to glycosylation: protein folding in the ER, proteoglycane synthesis in the 
Golgi apparatus and protein glycosylation, which involves both compartments. The 
double immunofluorescence stainings clearly indicate a Golgi localization of CANT1, 
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moreover, the diffuse cytoplasmic CANT1 staining, which was observed in these 
immunofluorescence stainings as well as in the immunohistochemical stainings, 
might indicate additional ER localization. Various studies dealing with C. elegans, 
CHO cells or patients that suffer from a rare type of Desbuquois chondrodysplasia 
mainly point to an involvement of CANT1 in protein folding and proteoglycane 
synthesis. APY-1, the C. elegans homologue of CANT1, is induced upon ER stress 
and knockdown of APY-1 leads to a constitutive unfolded protein response (UPR) 27. 
Additionally, the rat homologue of CANT1 colocalizes with an UPR sensor in the pre-
Golgi intermediates when transfected into CHO cells 12. In patients suffering from 
Desbuquois dysplasia, who frequently display mutations in the CANT1 gene 28, 
inclusion bodies were detected in distended rough ER 29, which might be a hint for 
impaired protein folding and subsequent accumulation of misfolded proteins. Hence, 
by interfering with protein folding, CANT1 knockdown possibly causes the disruption 
of various cellular processes, amongst others cell proliferation and migration. It is 
tempting to speculate that this explains the significantly reduced rate of proliferation 
and migration, which we observed in prostate cancer cell lines upon knockdown of 
CANT1. A participation of CANT1 in proteoglycane synthesis is substantiated by the 
finding that bone specimens of Desbuquois dysplasia patients are characterized by a 
decreased amount of proteoglycanes 30. Furthermore, C. elegans APY-1 loss-of-
function mutants display pharyngeal alterations resembling mutants defective in 
proteoglycane synthesis 27. An impaired proteoglycane synthesis upon CANT1 
downregulation could imply a miscomposed extracellular matrix and thus affect cell 
motility. Finally, the influence of CANT1 expression on glycosylation patterns of 
proteins has not been investigated yet and ought to be clarified in future studies.  
In confirmation of Smith et al. 3 we demonstrated that a soluble form CANT1 is 
secreted, since it was detectable in the supernatant after separation of vesicles by 
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ultracentrifugation. The function of this truncated form of the protein is currently 
unknown. 
To what extent the possible involvement of CANT1 in NFκB and MAPK 
signaling, in protein folding, proteoglycane synthesis and protein glycosylation refers 
to the here described effects remains to be elucidated in future studies. The fact that 
CANT1 overexpression in contrast to knockdown does not influence cell proliferation 
or migration indicates that CANT1 function is saturable and thus favors a role of 
CANT1 in glycosylation rather than in NFκB or MAPK signaling.  
Another open question is how CANT1 itself is regulated in prostate cancer. 
Probably, this involves androgen receptor signaling, as CANT1 was shown to be 
induced upon androgen treatment 5. Within this study the expression of two CANT1-
transcripts coding for the same protein was described in the prostate, one of them 
being prostate specific. If CANT1 regulation is transcript-specific or if other 
mechanisms play a role, will also be a matter of future research. Further, a mutation 
analysis of CANT1 in human prostate cancers could contribute to explain CANT1 
regulation and function.  
In summary, this study depicted detailed CANT1 expression patterns in 
different stages of prostate carcinogenesis. The protein level is low in normal prostate 
epithelium, increases at the early stage of PIN, remains constant in primary prostate 
carcinomas and metasases and decreases to an intermediate level in castrate 
resistant carcinomas. Under consideration of heterogeneity, a corresponding 
correlation between very high CANT1 levels in prostatectomy specimens and good 
prognosis was revealed. More important, we show that CANT1 expression is involved 
in prostate cancer cell proliferation and migration and thus demonstrate a functional 
relevance of CANT1 in a neoplasia. These results contribute to a better 
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understanding of prostate cancer molecular biology and recommend further studies 
to clarify the mechanisms of CANT1 function and regulation in prostate 
carcinogenesis. 
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Figure legends. 
Fig. 1 CANT1 immunohistochemistry of human prostatic tissues. 
Chromogenic immunohistochemistry of human prostatic tissues, magnification 200x if 
not otherwise indicated. A) Normal prostate glands, magnification 400x. B) Prostate 
adenocarcinoma infiltrating inbetween normal glands (N). C) Prostate 
adenocarcinoma, note the strong diffuse cytoplasmic staining. D) Prostate cancer 
metastasis in the lung, note the lymphocytes in the upper left corner. 
 
Fig. 2 CANT1 staining intensity in human prostatic tissue samples and 
univariate survival analysis.  
A) Mean CANT1 staining intensity on TMA #1 during neoplasia progression, p-values 
are put together in Table 3. B) Kaplan-Meier curves of CANT1 Golgi and cytoplasmic 
expression in cohort #1, dichotomized by the median in low (blue) and high (green) 
levels. C) Mean CANT1 staining intensity on TMA #2 in normal, prostate 
intraepithelial neoplastic and cancer tissue. D) Kaplan-Meier curve of CANT1 Golgi 
expression in cohort #2, green: upper quartile, blue: lower three quartiles of H-score 
in cancer tissue. Abbreviations: Ca=carcinoma, CRPC=castrate resistant prostate 
carcinoma, PIN=prostatic intraepithelial neoplasia, staining scores: 0=negative, 
1=weak, 2=moderate, 3=strong. 
 
Fig. 3 Cellular localization of CANT1. 
Double immunofluorescence of CANT1 and GOLPH2 in human prostatic tissues, left 
prostate adenocarcinoma, right normal prostate epithelium, magnification 400x.  
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 Fig. 4 Secretion of CANT1 and ELISA of human sera. 
A) 600’000 LNCaP and 400’000 PC-3 cells were seeded in 6 cm-dishes, at 70% 
density complete medium was washed away and replaced by serum-free medium. 24 
hours later supernatants were cleared from cell debris and afterwards vesicles were 
pelleted by ultracentrifugation. Soluble CANT1 was precipitated and analyzed by 
Western blotting together with lysates from the same cells. B) CANT1 was detected 
by a sandwich ELISA in 38 serum samples (15 healthy controls and 23 prostate 
cancer patients). Displayed are boxplots of the different groups.  
 
Fig. 5 Characterization of CANT1 expression in prostatic cell lines. 
Cells were cultivated and treated as described below and CANT1 mRNA and protein 
expression was determined by QRT-PCR (top) and Western blot analysis (bottom), 
respectively. A) LNCaP, DU-145, PC-3 and RWPE-1 cells were cultivated in T75-cell 
culture flasks until a density of 70% to 80%. 300’000 LNCaP (B) and 200’000 PC-3 
cells (C) were seeded into 6 well-plates, transfected with siRNAs as indicated and 
incubated for 72 hours. 
 
Fig. 6 Proliferation of prostate cancer cell lines upon CANT1 knockdown. 
300’000 LNCaP (A) and 200’000 PC-3 cells (B) were seeded in 6 well-plates, 
transfected with siRNAs as indicated and counted after 72 hours. 600’000 LNCaP (C) 
and 400’000 PC-3 cells (D) were seeded in 6 cm-dishes and transfected with siRNAs 
as indicated. After 72 hours 20’000 LNCaP and 10’000 PC-3 cells were reseeded in 
quadruplicates into 96 well-plates and DNA synthesis rate was measured.  
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 Fig. 7 Cell cycle distribution in CANT1 knockdown cells. 
500’000 LNCaP cells (A, C, E) and 200’000 PC-3 cells (B, D, F) that were left 
untreated (due to higher proliferation rates, compare Fig. 6a,b) or 600’000 LNCaP 
cells (A, C, E) and 400’000 PC-3 (B, D, F) cells that were transfected with siRNAs as 
indicated were seeded in 6 cm-dishes. After 72 hours cell cycle analysis was 
performed as described above. A, B) Representative histograms of cells that were 
treated either with unspecific siRNA (red) oder CANT1 siRNA#1 (blue) are shown, 
note the higher G1-phase peak and lower S-phase plateau and G2-phase peak in the 
CANT1 siRNA-histogram compared to the unspecific siRNA-histogram. C, D) 
Representative distribution of G1-, S- and G2/M-phase. E, F) Proportion of cells in 
G1-phase from all replicates. 
 
 
Fig. 8 Migration of prostate cancer cell lines upon CANT1 knockdown. 
600’000 LNCaP (A) and 400’000 PC-3 cells (B) were seeded in 6 cm-dishes and 
transfected with siRNAs as indicated. After 72 hours 50’000 cells were reseeded in 
triplicates into fibronectin coatet transwell chambers. 24 hours later the migrated cells 
were quantified by DAPI staining. Aside representative pictures of the membranes 
are displayed (magnification 100x). C) 400’000 PC-3 cells were seeded in 6 cm-
dishes and the scratch wound assay was conducted as described above. Aside 
representative pictures of the wounds are shown (magnification 25x). 
 
Fig. 9 Proliferation and Migration of a prostate epithelium cell line upon CANT1 
overepxression. 
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1.2 x 106 RWPE-1 cells were seeded in 6 cm-dishes and cultured for three days 
before transfection with GFP or CANT1 vector as indicated, the GFP/CANT1-mixture 
contained 5.33 µg GFP vector and 2.67 µg CANT1 vector. A) CANT1 mRNA 
expression was measured by QRT-PCR (top, one measurement) and protein 
expression of CANT1 and GFP was determined by Western blot analysis (bottom, 
representative blot from three independent experiments), respectively. B) The day 
after transfection 20’000 cells were reseeded in quadruplicates into 96 well-plates 
and DNA synthesis rate was measured. C) The day after transfection 100’000 cells 
were reseeded in triplicates into fibronectin coatet transwell chambers. 24 hours later 
the migrated cells were quantified by DAPI staining. 
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Table 1 Relationship between CANT1 expression and clinicopathological data 
of primary prostate carcinoma specimens (RPE) in cohort #1. 
 n=238 Golgi staining cytoplasmic staining 
parameter median (range) / 
cases (percentage) 
CANT1 
low 
CANT1 
high 
p-value CANT1 
low 
CANT1 
high 
p-value 
age  65 (50-77)     0.894     0.782 
    ≤ 64 years  68 46  78 36  
    > 64 years  76 48   82 42   
pre-OP PSA  12.3 (0.2-209)     0.669     0.026* 
    ≤ 10 ng/ml  55 35  51 39  
    > 10 ng/ml  67 49   84 32   
Gleason score       0.764     0.823 
    5-6 37 (15.5%) 21 16  24 13  
    7 138 (58%) 86 52   95 43   
  8-10 63 (26.5%) 37 26   41 22   
pT status       0.893     0.069 
    pT2 142 (59.7%) 85 57  102 40  
    pT3/4 96 (40.3%) 59 37   58 38   
margin status       0.583     0.563 
    R0 150 (63%) 92 58  100 50  
    R1 85 (35.7%) 49 36   60 25   
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Table 2 Relationship between CANT1 expression and clinicopathological data 
of primary prostate carcinoma specimens (RPE) in cohort #2. 
 n=640 Golgi staining 
parameter median (range) / 
cases (percentage) 
CANT1 
low 
CANT1 
high 
p-value 
age  62 (43-74)     0.273 
    ≤ 62 years  196 116  
    > 62 years  205 100   
pre-OP PSA  7.2 (0.8-39)     0.701 
    ≤ 10 ng/ml  293 153  
    > 10 ng/ml  104 59   
Gleason score       0.054 
    5-6 234 (36.6%) 136 84  
    7 293 (45.8%) 185 103   
    8-10 112 (17.5%) 80 29   
pT status       0.014* 
    pT2 442 (69.1%) 262 162  
    pT3/4 197 (30.8%) 139 54   
margin status       0.569 
    R0 463 (72.3%) 287 159  
    R1 173 (27%) 113 55   
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Table 3 Statistics of staining intensities on TMA#1 (p-values). 
Golgi staining normal primary Ca metastasis CRPC tumor 
normal - <0.0001* <0.0001* 0.009* <0.0001* 
primary Ca  - 0.889 0.008* - 
metastasis   - 0.053 - 
      
cytoplasmic staining normal primary Ca metastasis CRPC tumor 
normal - <0.0001* 0.001* 0.152 <0.0001* 
primary Ca  - 0.489 0.012* - 
metastasis   - 0.028* - 
 
For abbreviations see Fig. 2, the category “tumor” includes primary 
carcinomas, metastases and castrate resistant carcinomas. 











 Supplemental Figure S1 Blocking of immunohistochemistry with recombinant 
protein.  
A, B) Consecutive slides of Prostate adenocarcinoma stained with CANT1 antibody, 
magnification 25x. B) antibody pre-incubated with CANT1 recombinant protein.  
 
 Fig. S2 Cell cycle distribution in CANT1 knockdown cells (S-Phase). 
500’000 LNCaP cells (A) and 200’000 PC-3 cells (B) that were left untreated (due to 
higher proliferation rates, compare Fig. 6a,b) or 600’000 LNCaP cells and 400’000 
PC-3 cells that were transfected with siRNAs as indicated were seeded in 6 cm-
dishes. After 72 hours cell cycle analysis was performed as described above. 
Proportion of cells in S-phase from all replicates is shown. 
 
